Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.
about
Wnt5a Signaling in CancerGlycogen synthase kinase-3β is a pivotal mediator of cancer invasion and resistance to therapyExosomes-mediate microRNAs transfer in breast cancer chemoresistance regulationTargeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein HomeostasisInforming materials: drugs as tools for exploring cancer mechanisms and pathways.Minimizing bias in target selection by exploiting multidisciplinary Big Data and the protein interactome.Mitochondrial DNA somatic mutation in cancerPersonalized targeted therapy for esophageal squamous cell carcinoma.Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients.Resistance to targeted cancer drugs through hepatocyte growth factor signalingInhibition of SALL4 suppresses carcinogenesis of colorectal cancer via regulating Gli1 expression.Activin a signaling regulates cell invasion and proliferation in esophageal adenocarcinomaActivation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.Immunomediated Pan-cancer Regulation Networks are Dominant Fingerprints After Treatment of Cell Lines with Demethylation.Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2.A Hybrid Drug Limits Resistance by Evading the Action of the Multiple Antibiotic Resistance Pathway.Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?Associations Between Elastography Findings and Clinicopathological Factors in Breast Cancer.Everolimus induces Met inactivation by disrupting the FKBP12/Met complexOxidative Stress, Nrf2, and Epigenetic Modification Contribute to Anticancer Drug Resistance.Blockade of the Hedgehog pathway downregulates estrogen receptor alpha signaling in breast cancer cells.Resistin confers resistance to doxorubicin-induced apoptosis in human breast cancer cells through autophagy induction.Photochemical activation of drugs for the treatment of therapy-resistant cancers.Targeting tumor suppressor genes for cancer therapy.In situ analysis of FGFR2 mRNA and comparison with FGFR2 gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.Cellular determinants and microenvironmental regulation of prostate cancer metastasis.Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint.Molecular mechanisms for tumor resistance to chemotherapy.Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer.Defective phosphoinositide metabolism in autism.Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy.The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cellsCorrigendum: Discoidin Domain Receptors: Potential Actors and Targets in Cancer.Tumorigenesis as a process of gradual loss of original cell identity and gain of properties of neural precursor/progenitor cells.A simple reduction-sensitive micelles co-delivery of paclitaxel and dasatinib to overcome tumor multidrug resistance.A comparison of cell survival and heat shock protein expression after radiation in normal dermal fibroblasts, microvascular endothelial cells, and different head and neck squamous carcinoma cell lines.Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression.Isocorydine suppresses doxorubicin-induced epithelial-mesenchymal transition via inhibition of ERK signaling pathways in hepatocellular carcinoma.
P2860
Q26738408-1F30B86D-36CD-489E-8480-B412DA01E2D9Q26739711-8374F0D6-E05F-4A62-AD72-A2409779EBBBQ28066991-80E56B7B-13A1-490B-A3A1-9428E4A37307Q28269674-6733D090-E2E9-448D-B388-7E50A155A243Q30402161-2A95D892-8CE8-4452-A11A-BDF215C56D73Q31125908-F0A997F1-40C1-487F-8A83-848435B6D1D3Q34906440-CAFBCF14-2254-4600-AEDB-385350969F34Q35819517-4B9F73B2-83D3-4EB0-A25D-E396157AF071Q35885488-BA45B066-D45C-4320-895D-DA409BBA32C5Q36189390-773160F7-CD25-4FCF-880B-555AB514D4D4Q36261279-B16F0023-C043-42B1-BA01-725D2AC2A387Q36544056-0E38F4C2-2B3B-46F0-8092-A6E2173B833BQ36765341-271AAC9A-E756-44D0-BD62-08EE2910FAFFQ36848243-9F1B806F-A5AB-4E28-96FC-D5A4A6C33601Q37206023-8203E226-19F4-42C6-989A-219EFE2B0FE7Q37229409-A5726D84-F155-436E-A6F4-629827EDF13CQ37242412-9A3B2464-76B2-46B8-B914-BCEBD0AB27D3Q37328400-A8373AB2-AA2D-4440-AEB7-7DF480762288Q37457794-36BB26D8-7326-484D-9FB4-5D7C76856A4DQ37606602-5961A054-E80D-4E3A-8BEC-F89818737ACAQ37687668-FCF5B27F-12A7-45A3-9114-9AD97AA38857Q37743518-29C21A91-BFF4-46A1-A1E4-DE10D91BDAABQ38409528-62089300-92A9-4769-9AE6-54039A048FDBQ38601568-52B34AFD-7795-46D1-A787-2CD51BBF1971Q38602669-E9AFA9FB-A550-4E88-95CB-AF07707E84CDQ38730590-A3F66875-22C7-47D0-B376-7DEFE93B06E7Q38748101-D4EF4535-04EC-4D5D-ACC9-78CA33BD0588Q38813053-50D58580-DF63-4B1B-9EE9-0B949CF6ED53Q38822335-D472D9B9-2B4B-44FC-A5C6-B08DE66E45D4Q38826542-89895FAD-3322-4668-B69E-27CA59392A22Q38885442-80C0C7DD-8BFB-4C56-9320-B6D4827A1CC1Q38969204-4FCDDBFC-B305-41AB-944C-90BAED9D2660Q39400469-9BC747B2-8B8E-4CFB-B8A2-1B22D1BABC81Q42038363-E0716A03-85B6-4C20-AA78-3E362E9E3AD4Q42389463-0D145B85-5034-427B-ACB3-43355E5FC59EQ47140201-D5EBA425-2341-4CE1-8E51-CF5D7D17B01EQ47156317-BE22E587-E30A-4032-A7A9-8F757CC0D461Q47226956-243ED132-71F2-450D-962C-14D63E7D1270Q47671139-28FA1749-D964-4D40-9EBB-A7045C1D6A27Q48507168-21B82214-144E-4587-84A8-4B53364942A0
P2860
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.
@en
type
label
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.
@en
prefLabel
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.
@en
P2860
P356
P1433
P1476
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.
@en
P2093
P2860
P2888
P304
P356
10.1038/ONC.2014.314
P407
P577
2014-09-29T00:00:00Z
P6179
1001342368